CopyMark Law Group
4.9/5
Drawing for BECOME THE BREAKTHROUGH

USPTO serial 97113881

BECOME THE BREAKTHROUGH

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
BELL, MARLENE D
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with BECOME THE BREAKTHROUGH?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Trademark Monitoring
(312) 319-4460
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Start a new application
(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Rachelle A. Dubow, Esq.

Rachelle A. Dubow, Esq. MORGAN, LEWIS & BOCKIUS LLPONE FEDERAL STREETBOSTON, MA 02110United States

Goods and services

ClassDescriptionStatusFirst use
035Recruitment advertisement services, namely, contacting physicians for the purpose of recruiting patients for participation in clinical trials for the testing of drugs by means of direct methods of marketing, namely, e-mail marketing, SMS messaging, electronic medical record (EMR) messaging, in-clinic communications, in-clinic promotional material, and telephone calls, and indirect methods of marketing communications, namely, social media, search engine marketing, inquiry marketing, internet marketing, mobile marketing, blogging and other forms of passive, sharable or viral communications channels of clinical trial notices for the purpose of recruiting patients for participation in clinical trials for the testing of drugs; business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approvalACTIVE—
042Conducting clinical trials for others; Providing medical and scientific research information in the field of clinical trials; Consulting services for others in the field of design, planning, and implementation project management of clinical trialsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Jul 27, 2026MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jul 27, 2026ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
May 13, 2026EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
May 12, 2026EX5GSOU EXTENSION 5 GRANTED—
May 12, 2026AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Dec 15, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Dec 14, 2025EXT5SOU EXTENSION 5 FILED—
Jun 19, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jun 18, 2025EX4GSOU EXTENSION 4 GRANTED—
Jun 18, 2025EXT4SOU EXTENSION 4 FILED—
Jun 18, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Dec 20, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Dec 20, 2024EX3GSOU EXTENSION 3 GRANTED—
Dec 20, 2024EXT3SOU EXTENSION 3 FILED—
Dec 20, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 20, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jun 20, 2024EX2GSOU EXTENSION 2 GRANTED—
Jun 20, 2024EXT2SOU EXTENSION 2 FILED—
Jun 20, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Dec 22, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Dec 20, 2023EX1GSOU EXTENSION 1 GRANTED—
Dec 20, 2023EXT1SOU EXTENSION 1 FILED—
Dec 20, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 20, 2023NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Apr 25, 2023NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Apr 25, 2023PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 5, 2023NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 18, 2023CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 28, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Feb 27, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 27, 2023TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 27, 2022GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 27, 2022GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 27, 2022CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 17, 2022DOCKASSIGNED TO EXAMINER—
Nov 16, 2021NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Nov 11, 2021NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance